Abstract
Background: Pistagremic acid; 3-methyl-7-(4,4,10,13,14-pentamethyl-3-2,3,4,5,6,7,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthr-en-17-yl)-oct-3-enoic acid was isolated from the chloroform fraction of Pistacia integerrima. Cytotoxic evaluation against NCI-60 DTP human tumor cell line was performed. Methods: The anticancer assays for this compound were performed in accordance with the protocol of the Drug Evaluation Branch, by the National Cancer Institute (NCI) Developmental Therapeutic Program (www.dtp.nci.nih.gov) to be screened for their anticancer activity in vitro. Results: It showed broad spectrum antiproliferative activity with an average GI50, and TGI, values 0.103 μM and 0.259 μM, respectively. It also showed significant LC50 value at the average 0.634 μM against all cell lines excluding K-562, RPMI-8226, NCI-H226, and NCI-H460 cell-lines. Conclusions: Pistagremic acid showed cytotoxicity for all tested cancer cell line, thus it may serve as a potential structure lead for the development of new anticancer drugs.
Highlights
Pistacia integerrima belongs to family Anacardiacea and found in eastern Himalayan range [1]
In continuation of our previous investigation on the bioactivities of pistagremic acid (Figure 1) [11], which was evaluated for its cytotoxic effects against NCI 60-cell panel on eight organs at National Cancer Institute (NCI) USA, showed significant inhibition of human cancer cell lines
Pistacia integerrima galls were collected from Razagram, Khyber Pakhtunkhwa, Pakistan in February, 2010 and identified as P. integerrima by Prof
Summary
Pistacia integerrima belongs to family Anacardiacea and found in eastern Himalayan range [1]. Various types of cancer reported, cancers of the prostate, lung, and liver the most commonly reported worldwide. Researchers have been spending several decades to identify effective agents against cancer which is one of the leading causes of death worldwide. The management of cancer is still not up to mark and always needs to find out new chemotherapeutic agents. In continuation of our previous investigation on the bioactivities of pistagremic acid (Figure 1) [11], which was evaluated for its cytotoxic effects against NCI 60-cell panel on eight organs (leukemia, non-small cell lung cancer, colon, CNS, melanoma, ovarian, prostate, renal and breast) at National Cancer Institute (NCI) USA, showed significant inhibition of human cancer cell lines. Pistagremic acid; 3-methyl-7-(4,4,10,13,14-pentamethyl-3-2,3,4,5,6,7,10,11,12,13,14,15,16,17tetradecahydro-1H-cyclopenta[a]phenanthr-en-17-yl)-oct-3-enoic acid was isolated from the chloroform fraction of Pistacia integerrima. Cytotoxic evaluation against NCI-60 DTP human tumor cell line was performed
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
